schizophrenia

Oct 18, 2024

Key Highlights  INVEGA and VRAYLAR (US)/REAGILA (EU) (cariprazine) accounted for the major share of the revenue market for schizophrenia patients in 2023. However, according to DelveInsight, this share is expected to decline by 2034 due to the launch of new emerging therapies. Schizophrenia has a robust...

Oct 18, 2024

Schizophrenia and Bipolar Disorder are often challenging to differentiate due to their overlapping symptoms. Schizophrenia is primarily marked by hallucinations and delusions, leading individuals to lose touch with reality. Patients may hear voices or see things that aren’t there, creating a profound sense of detac...

Oct 18, 2024

Schizophrenia affects approximately 24 million people worldwide, or 1 in every 300 people (0.32%). In adults, this rate is 1 in 222 (0.45%). It is not as widespread as many other mental disorders. Onset occurs most frequently in late adolescence and the twenties, and it occurs earlier in men than in women. Schiz...

Oct 01, 2024

IntraBio's AQNEURSA Receives Historic FDA Approval for Niemann-Pick Disease Type C Treatment IntraBio Inc. has received approval from the FDA for AQNEURSA (levacetylleucine), marking a significant milestone in the treatment of neurological manifestations of Niemann-Pick disease type C  in both adults and pe...

Sep 30, 2024

After years of little progress in the field of schizophrenia drug treatment, Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics has paid off with the approval of a groundbreaking new drug. BMS’s novel medication, KarXT—now named COBENFY—received significant FDA approval on 26 September 2024 for t...

Apr 15, 2024

Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability. Evenamide, based on a new concept in treating inadequat...

Apr 12, 2024

Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia. Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A recept...

Apr 05, 2024

Fifteen years after its first FDA approval for treating schizophrenia with Fanapt (iloperidone), Vanda Pharmaceuticals has achieved another success. Fanapt is a type of antipsychotic medication that deviates from the usual and has been administered to individuals with schizophrenia for their immediate treatment fol...

Mar 19, 2024

Bristol Myers Squibb Enhances Neuroscience Arm with Karuna Therapeutics Buyout Bristol Myers Squibb has declared the finalization of its purchase of Karuna Therapeutics, Inc. With this acquisition concluded Karuna’s shares are no longer being traded on the Nasdaq Global Select Market, as Karuna is now fully owne...

May 02, 2023

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...